Feng Xiangping, Zhang Zongxin, Mao Shuiying
Clinical Laboratory, Huzhou Maternity & Child Health Care Hospital, Huzhou, China.
Clinical Laboratory, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, China.
Ann Med. 2025 Dec;57(1):2445781. doi: 10.1080/07853890.2024.2445781. Epub 2025 Jan 2.
The prognostic value of C-reactive protein (CRP) in patients with bladder cancer (BCa) has been widely analysed; however, the results remain conflicting. Therefore, we performed this meta-analysis to identify the precise role of CRP level in predicting BCa prognosis.
PubMed, Web of Science, Embase and Cochrane Library databases were comprehensively searched until 19 April 2024. The impact of CRP level on predicting the prognosis of patients with BCa was examined using combined hazard ratios (HRs) and 95% confidence intervals (CIs). The relationship between CRP level and BCa clinicopathological characteristics was investigated by combining the odds ratios (ORs) with 95%CIs.
Twenty studies with 7276 patients were enrolled in this study. As revealed by pooled data, elevated CRP levels were markedly related to poor overall survival (OS) (HR = 2.02, 95%CI = 1.41-2.90, < .001), inferior cancer-specific survival (CSS) (HR = 1.46, 95%CI = 1.29-1.66, < .001), shortened recurrence-free survival (RFS) (HR = 1.25, 95%CI = 1.17-1.33, < .001) and dismal progression-free survival (PFS) (HR = 2.28, 95%CI = 1.80-2.90, < .001) in BCa patients. Nevertheless, there was no significant relationship between CRP level and sex, tumour size, tumour grade or lymph node metastasis (LNM) in BCa.
Elevated CRP levels were significantly related to poor OS, CSS, RFS and PFS of BCa patients with BCa. CRP could act as a reliable biomarker for predicting the short- and long-term survival of patients with BCa in clinical practice.
C反应蛋白（CRP）在膀胱癌（BCa）患者中的预后价值已得到广泛分析；然而，结果仍存在矛盾。因此，我们进行了这项荟萃分析，以确定CRP水平在预测BCa预后中的精确作用。
全面检索了PubMed、Web of Science、Embase和Cochrane图书馆数据库，直至2024年4月19日。使用合并风险比（HRs）和95%置信区间（CIs）来检验CRP水平对预测BCa患者预后的影响。通过将比值比（ORs）与95%CI相结合，研究CRP水平与BCa临床病理特征之间的关系。
本研究纳入了20项研究，共7276例患者。汇总数据显示，CRP水平升高与BCa患者的总生存期（OS）较差（HR = 2.02，95%CI = 1.41 - 2.90，< 0.001）、癌症特异性生存期（CSS）较差（HR = 1.46，95%CI = 1.29 - 1.66，< 0.001）、无复发生存期（RFS）缩短（HR = 1.25，95%CI = 1.17 - 1.33，< 0.001）和无进展生存期（PFS）不佳（HR = 2.28，95%CI = 1.80 - 2.90，< 0.001）显著相关。然而，BCa患者的CRP水平与性别、肿瘤大小、肿瘤分级或淋巴结转移（LNM）之间无显著关系。
CRP水平升高与BCa患者的OS、CSS、RFS和PFS较差显著相关。在临床实践中，CRP可作为预测BCa患者短期和长期生存的可靠生物标志物。
